Investigate / reported ownership
ABT
Abbott Laboratories
8 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.
Who reports owning ABT?
Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Joel Greenblatt | 0.4% | 38q | $780M | 8,597,227 |
| 2 | Jensen Investment Management | 1.9% | 40q | $80M | 885,262 |
| 3 | Mason Hawkins | 4.0% | — 1q | $76M | 840,747 |
| 4 | Mairs & Power Funds | 0.6% | 40q | $66M | 729,358 |
| 5 | David Katz | 0.3% | 3q | $4M | 47,262 |
Go beyond ownership.
Abbott sells a broad, diversified line of healthcare products, with customers paying for medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
Question to investigate: Can Abbott integrate its cancer diagnostics acquisition and keep its other healthcare product lines contributing without added acquisition-related strain?
Company research reviewed 2026-10-02; a dated source-linked starting point, not the investors’ stated reasons.
Understand the business and investment case →Filing dates and original SEC sources
- Joel Greenblatt · 2026Q2 · filed 2026-09-02 ↗
- Jensen Investment Management · 2026Q2 · filed 2026-08-07 ↗
- Mason Hawkins · 2026Q2 · filed 2026-08-14 ↗
- Mairs & Power Funds · 2026Q2 · filed 2026-08-14 ↗
- David Katz · 2026Q2 · filed 2026-07-15 ↗
- Dodge & Cox Funds · 2026Q2 · filed 2026-08-13 ↗
- Thomas Russo · 2026Q2 · filed 2026-08-13 ↗
- Polen Capital Management · 2026Q2 · filed 2026-08-04 ↗
Reported position changes
Net disclosed share changes—not individual trades or execution dates. NEW has no prior-position percentage comparison; EXIT weight refers to the previous report.
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Mason Hawkins | NEW | 4.0% | New position | $76M | Aug 14, 2026 |
Keep your next step small.
Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.
Record my own view →Optional email follow
Latticework Follow
Follow ABT
Email me only when a reviewed weekly edition contains a material new decision about ABT: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.
Confirm by email. Manage or stop follows in one click. See our privacy notice.
Long US 13F disclosures omit shorts and can be amended. CUSIP 002824100. No current price, valuation or manager motive is inferred.